September 3, 2019 / 12:13 PM / 19 days ago

Vertex to buy cell therapy developer Semma for $950 mln

Sept 3 (Reuters) - Vertex Pharmaceuticals Inc said on Tuesday it would buy privately held Semma Therapeutics for $950 million in cash to develop stem-cell based treatments for diabetes.

Semma is developing stem-cell derived therapies as a potentially curative treatment for type 1 diabetes. (Reporting by Manas Mishra in Bengaluru; Editing by Arun Koyyur)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below